NAMS updated its position statement on hormone therapy (2017), based on an extensive literature review. Hormone therapy (HT) is the most effective treatment for vasomotor symptoms (VMS; hot flashes, night sweats) and genitourinary syndrome of menopause (GSM).
Contraindications for HT
Potential risks of HT
FDA approved indications for HT
NAMS recommendations for type / regimen / duration of use
NAMS recommendations for special populations and cancer risk
Hormonal therapy dosage / regimens
Key points
Learn more
(Level I: Based on good and consistent scientific evidence / Level II: Based on limited or inconsistent scientific evidence / Level III: Based primarily on consensus and expert opinion)
NOTE: For women with a uterus and using systematic estrogen, ensure endometrial protection with an adequate dose of a progestogen
Note:
*D recommendation Suggestion for Practice: Discourage the Use of This Service
Want to be notified when new guidelines are released? Get ObGFirst! Tap Here »
The 2017 hormone therapy position statement of The North American Menopause Society
ACOG Practice Bulletin 141: Management of Menopausal Symptoms
Practice Bulletin 141: Management of Menopausal Symptoms: Correction
Kaunitz and Manson: Management of Menopausal Symptoms
USPSTF: Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women
Please log in to ObGFirst to access the 2T US Atlas